Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Growth hormone-deficient young adults need larger replacement doses than older adults

06.11.2003


Young adults who received growth hormone treatment as children for deficiencies in producing that essential hormone likely will need continued treatment for years and at higher doses than doctors now prescribe, a new multi-center North American study concludes.



Higher doses of the hormone should help protect such patients from excessive and eventually crippling declines in the density of their bones and from higher blood levels of harmful fats that could promote heart disease, researchers say. Earlier reports suggested growth hormone also helped maintain healthy muscle mass and lessened depression, a common complaint among patients.

A report on the study, conducted over two years at 12 U.S. and five Canadian medical centers, appears in the November issue of the Journal of Clinical Endocrinology & Metabolism.


Dr. Louis Underwood, professor of pediatrics at the University of North Carolina at Chapel Hill School of Medicine, led the research. Co-authors of the paper were Drs. Kenneth M. Attie and Joyce Baptista of Genentech Inc. of San Francisco and the Genentech Collaborative Study Group.

"We did this randomized, double-blind, placebo-controlled trial to improve our understanding of what doses we should give young adults who need treatment," said Underwood. "We believe our findings will change clinical practice in the United States and abroad."

Typically, doctors treat growth hormone-deficient children with hormone doses that reach a peak in late adolescence when the naturally secreted compound reaches its maximum in healthy children, he said. As patients age into adulthood, clinicians often stop treatment to determine whether there is a continued need. If so, treatment is restarted at significantly lower doses since older adults need less growth hormone and cannot tolerate it as well as children.

"Besides the placebo, which is inactive, we tested a dose of 25 micrograms per kilogram of body weight per day and also a dose that was half that large," Underwood said. "The 25 microgram dose is about half of what is used in children."

The medical scientists studied 39 men and 25 women, all under age 35, and looked especially at what happened to their bone mineral density, depending on whether or not they received growth hormone and how much.

"Compared with the placebo group, patients who got 12.5 micrograms showed better bone mineral density after two years," Underwood said. "Those who received 25 micrograms per kilogram daily showed an even greater and more sustained effect."

Both growth hormone-treated groups had similar changes in body composition at six months -- decreased fat and increased lean mass -- but some improvements were later lost in the lower-dose group, he said.

"A significant decrease in low-density lipoprotein cholesterol, which is believed to be bad for a person’s health, was seen only in the higher growth hormone dose group," Underwood said. "We did not observe significant changes in quality of life or echocardiograph measures."

Adverse effects among study groups were about the same except that the hormone-treated groups showed more swelling, a common side effect of such treatment in adults, he said.

Genentech supported the research. Collaborating institutions in the United States included Children’s Hospital Medical Center in Cincinnati, Kansas Medical Center, the Medical College of Wisconsin, the Oregon Health Sciences University, Stanford University and the universities of California at Los Angeles and Michigan. Canadian institutions included Children’s Hospital in Winnipeg, Children’s Hospital of Western Ontario, Central University Hospital in Sherbrooke, Quebec, the Research Center of Hotel-Dieu of Montreal and Central Hospital of Laval University in Ste.-Foy, Quebec.

In the 1970s, Dr. Judson J. Van Wyk, Underwood and UNC colleagues purified a compound known as IGF-1 and developed an assay for it. IGF-1, or insulin-like growth factor 1, is a growth-hormone-dependent protein that mediates many of the growth-promoting actions of growth hormone.

Now, doctors around the world monitor the effect of growth hormone therapy in hormone-deficient adults by testing their levels of IGF-1, which is made throughout the body but chiefly in the liver. The brain’s pea-sized pituitary gland produces growth hormone.

David Williamson | EurekAlert!
Further information:
http://www.med.unc.edu

More articles from Studies and Analyses:

nachricht Researchers simplify tiny structures' construction drip by drip
12.11.2018 | Princeton University, Engineering School

nachricht Mandibular movement monitoring may help improve oral sleep apnea devices
06.11.2018 | Elsevier

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: A Chip with Blood Vessels

Biochips have been developed at TU Wien (Vienna), on which tissue can be produced and examined. This allows supplying the tissue with different substances in a very controlled way.

Cultivating human cells in the Petri dish is not a big challenge today. Producing artificial tissue, however, permeated by fine blood vessels, is a much more...

Im Focus: A Leap Into Quantum Technology

Faster and secure data communication: This is the goal of a new joint project involving physicists from the University of Würzburg. The German Federal Ministry of Education and Research funds the project with 14.8 million euro.

In our digital world data security and secure communication are becoming more and more important. Quantum communication is a promising approach to achieve...

Im Focus: Research icebreaker Polarstern begins the Antarctic season

What does it look like below the ice shelf of the calved massive iceberg A68?

On Saturday, 10 November 2018, the research icebreaker Polarstern will leave its homeport of Bremerhaven, bound for Cape Town, South Africa.

Im Focus: Penn engineers develop ultrathin, ultralight 'nanocardboard'

When choosing materials to make something, trade-offs need to be made between a host of properties, such as thickness, stiffness and weight. Depending on the application in question, finding just the right balance is the difference between success and failure

Now, a team of Penn Engineers has demonstrated a new material they call "nanocardboard," an ultrathin equivalent of corrugated paper cardboard. A square...

Im Focus: Coping with errors in the quantum age

Physicists at ETH Zurich demonstrate how errors that occur during the manipulation of quantum system can be monitored and corrected on the fly

The field of quantum computation has seen tremendous progress in recent years. Bit by bit, quantum devices start to challenge conventional computers, at least...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

“3rd Conference on Laser Polishing – LaP 2018” Attracts International Experts and Users

09.11.2018 | Event News

On the brain’s ability to find the right direction

06.11.2018 | Event News

European Space Talks: Weltraumschrott – eine Gefahr für die Gesellschaft?

23.10.2018 | Event News

 
Latest News

The dawn of a new era for genebanks - molecular characterisation of an entire genebank collection

13.11.2018 | Life Sciences

Fish recognize their prey by electric colors

13.11.2018 | Life Sciences

Ultrasound Connects

13.11.2018 | Awards Funding

VideoLinks
Science & Research
Overview of more VideoLinks >>>